The UPMC Immune Transplant and Therapy Center is also a collaborating and sometimes leading site for industry-sponsored trials researching:
- Tumor infiltrating lymphocytes (TILs) for a range of metastatic and recurrent cancers.
- Chimeric antigen receptor (CAR) T-cell therapies for refractory/relapsed lymphoma and leukemia.
Our researchers are also designing novel applications and enhancements of CAR T cells, with a focus on improving and optimizing their use.